Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
autoimmune disease
Biotech
Candid flashes big ambitions with $370M debut
Candid’s launch combines fundraising and the acquisition of two biotechs, Vignette Bio and TRC 2004, along with their lead assets.
Darren Incorvaia
Sep 9, 2024 9:00am
Bicara, Zenas seek IPOs to push late-phase assets toward market
Aug 23, 2024 5:07am
J&J vets burst into biotech with $165M Third Arc series A
Jul 23, 2024 10:00am
In first, autoimmune patients respond to allogeneic CAR-T cells
Jul 17, 2024 3:26pm
Artiva plans IPO to fund NK cell therapy's autoimmune trials
Jul 1, 2024 7:48am
CAR-T therapy for lupus nets ‘Insight’ prize for researchers
Jun 21, 2024 4:30am